AI Article Synopsis
- A 56-year-old male presented with chromoblastomycosis, characterized by large plaque and verrucous hyperplasia on his left upper limb and elbow abnormalities.
- Diagnosis was confirmed through gross and microscopic assessments, along with the identification of the causative agent, Fonsecaea nubica, using molecular tools.
- The patient successfully underwent a treatment regimen that included oral antifungals and thermotherapy, and a review of similar cases highlighted that other patients were also males over 30, with lesions following trauma.
Article Abstract
We report a case of chromoblastomycosis due to the presence of large plaque and verrucous hyperplasia lesions on the left upper limb, with elbow abnormal activities, in a 56-year-old male. The diagnosis of chromoblastomycosis was based on gross and microscopic morphologies, histopathological examination and clinical manifestation. Molecular tools were applied to identifying the causative agent Fonsecaea nubica, which is rarely reported to be associated with chromoblastomycosis. The patient was initially treated orally with terbinafine (250 mg/day) and itraconazole (200 mg/day), subsequently patient received thermotherapy (45-50°C, 3 h/day) for 1 month. The patient was successfully cured. A literature review was performed to assess general features, treatment and outcome of chromoblastomycosis due to F. nubica. All the 5 reviewed patients were male, over 30 years old and their lesions occurred after traumatic inoculation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/myc.12732 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the antifungal activity of the pyrimidine analogs flucytosine and carmofur against human-pathogenic dematiaceous fungi.
Med Mycol
March 2024
Mycology Laboratory, National Institute of Infectious Diseases Evandro Chagas, INI/Fiocruz, Rio de Janeiro, Brazil.
Article Synopsis
- Chromoblastomycosis (CBM) and pheohyphomycosis (PHM) are fungal infections caused by dematiaceous fungi, with flucytosine (5-FC) historically used for treatment but often leading to resistance.
- This study evaluated carmofur, a related drug, showing it has higher selectivity and potential synergistic effects when used with other antifungals against certain fungal strains.
- While carmofur demonstrated some advantages in combating resistance, it also faced its own challenges, indicating the need for careful consideration in its clinical use alongside other treatments.
New methylene blue-mediated photodynamic inactivation of multidrug-resistant Fonsecaea nubica infected chromoblastomycosis in vitro.
Braz J Microbiol
June 2023
Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
Chromoblastomycosis is a fungal disease presented with local warty papule, plaque, and verrucous nodules. In addition, the incidence and drug resistance of chromoblastomycosis are increasing each year worldwide. Photodynamic therapy is a promising method to treat mycoses.
View Article and Find Full Text PDFChromoblastomycosis is an implantation fungal infection. Twenty years ago, Madagascar was recognized as the leading focus of this disease. We recruited patients in Madagascar who had chronic subcutaneous lesions suggestive of dermatomycosis during March 2013-June 2017.
View Article and Find Full Text PDFA screening of the MMV Pathogen Box® reveals new potential antifungal drugs against the etiologic agents of chromoblastomycosis.
PLoS One
July 2020
Mycology Laboratory at the Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis caused by traumatic implantation of many species of black fungi. Due to the refractoriness of some cases and common recurrence of CBM, a more effective and less time-consuming treatment is mandatory. The aim of this study was to identify compounds with in vitro antifungal activity in the Pathogen Box® compound collection against different CBM agents.
View Article and Find Full Text PDF[Management of chromoblastomycosis, a challenge for limited-resource countries such as Madagascar].
Ann Dermatol Venereol
May 2020
USFR dermatologie, hôpital universitaire Joseph Raseta Befelatanana Antananarivo, Antananarivo, Madagascar.
Introduction: Chromoblastomycosis (CBM) is a chronic fungal infection of the skin and subcutaneous tissue caused by dematiaceous fungi. CBM lesions are recalcitrant and extremely difficult to eradicate. We report three cases of CBM with difficulties in therapeutic management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!